Skin Biopsy Distinguishes Body-First from Brain-First Parkinson’s Disease

The clinical heterogeneity of Parkinson’s disease complicates efforts to establish early diagnosis and predictable prognostic frameworks. While the accumulation of misfolded alpha-synuclein remains the definitive histopathological hallmark, its detection in cerebrospinal fluid and gastrointestinal tissues has shown inconsistent diagnostic sensitivity and specificity [1, 2, 3]. Recent evidence suggests that neurodegeneration may initiate in the peripheral autonomic nervous system before ascending to the brain, a body-first trajectory that contrasts with traditional brain-first models [4]. Identifying these distinct pathological pathways is essential for the success of disease-modifying therapies, particularly as clinicians seek accessible, repeatable biomarkers to monitor protein aggregation over time [5]. A recent study demonstrates how cutaneous tissue analysis can differentiate these divergent disease origins, offering a practical tool for clinical subtyping.